title: [Prostatic cancer between 50 and 60. A more than 20-year-long retrospective study. Apropos of 65 case reports].
abstract: Sixty five 50 to 60 year old patients have been treated for prostatic cancer over a 21 year period. Twenty four had a local prostatic cancer (A1, A2, B1, B2) and 41 (63.2%) a locally advanced or metastatic (D1, D2 disease at diagnosis. The mean age was 56 years old. As being as retrospective study, miscellaneous treatments were done. The 5 and 10 years survival, analysed with the Kaplan-Meier method, was 61% and 31% respectively. According to the stage of cancer, the 10 year survival was 72% and 5% for (A-B) and (C-D) respectively. For well differentiated tumors, 5 years survival was 67% instead of 36% for undifferentiated ones. The 10 year survival was 36% for well differentiated tumors with 6 on 8 patients who survived with a mean of 11.6 ears. The authors discussed the benefit of an early diagnosis of prostatic in the 50-60 year old men group which is 4% of the total prostatic cancer diagnosed within the same period. They analysed the influence of PSA and transrectal sonography interest at this age.
authors.affiliation: Service d'Urologie, Chu de Poitiers, France.
authors.forename: J
authors.initials: J
authors.lastname: Aubert
authors.forename: J
authors.initials: J
authors.lastname: Orget
authors.forename: D
authors.initials: D
authors.lastname: Bon
authors.forename: M
authors.initials: M
authors.lastname: Marroncle
mesh_terms: D001859:Bone Neoplasms / Q000556:secondary; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D017430:Prostate-Specific Antigen